Earnings Feed
Start Free
Home/Filings/4/0001179110-13-010237
4//SEC Filing

ONYX PHARMACEUTICALS INC 4

Accession 0001179110-13-010237

CIK 0001012140operating
View on SEC.govCompany Profile

Filed

Jun 11, 8:00 PM ET

Accepted

Jun 12, 8:32 PM ET

Size

22.4 KB

Accession

0001179110-13-010237

Insider Transaction Report

Form 4
Period: 2013-06-10
ONYX PHARMACEUTICALS INCONXX
WOOD JULIANNA R
VP, Corp. Communication/I.R.
Transactions
  • Exercise/Conversion

    Common Stock

    2013-06-10$30.28/sh+547$16,563→ 19,921 total
  • Exercise/Conversion

    Common Stock

    2013-06-10$35.18/sh+547$19,243→ 20,468 total
  • Sale

    Common Stock

    2013-06-10$92.30/sh−2,306$212,844→ 19,374 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-06-10−547→ 6,088 total
    Exercise: $30.28Exp: 2020-03-31→ Common Stock (547 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-06-10−219→ 5,869 total
    Exercise: $30.28Exp: 2020-03-31→ Common Stock (219 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-06-10−274→ 273 total
    Exercise: $28.55Exp: 2019-03-31→ Common Stock (274 underlying)
  • Exercise/Conversion

    Common Stock

    2013-06-10$37.68/sh+719$27,092→ 21,187 total
  • Exercise/Conversion

    Common Stock

    2013-06-10$30.28/sh+219$6,631→ 21,406 total
  • Exercise/Conversion

    Common Stock

    2013-06-10$28.55/sh+274$7,823→ 21,680 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-06-10−547→ 8,568 total
    Exercise: $35.18Exp: 2021-03-31→ Common Stock (547 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-06-10−719→ 17,010 total
    Exercise: $37.68Exp: 2022-03-29→ Common Stock (719 underlying)
Holdings

  • Common Stock

    (indirect: By Trust)
    200
Footnotes (3)
  • [F1]Shares sold pursuant to a 10b5-1 plan.
  • [F2]12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
  • [F3]Fully vested.

Documents

1 file

Issuer

ONYX PHARMACEUTICALS INC

CIK 0001012140

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001012140

Filing Metadata

Form type
4
Filed
Jun 11, 8:00 PM ET
Accepted
Jun 12, 8:32 PM ET
Size
22.4 KB
View on SEC.gov